Anzeige
❌
Mehr »
Mittwoch, 30.09.2026 - Börsentäglich über 12.000 News
Mega-Volltreffer: 24,3 Meter mit 10,14 g/t Gold
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
VB

WKN: A4205C | ISIN: CH1476899161 | Ticker-Symbol: J8L0
Frankfurt
30.09.26 | 17:47
1,022 Euro
-18,76 % -0,236
1-Jahres-Chart
VERAXA BIOTECH AG Chart 1 Jahr
5-Tage-Chart
VERAXA BIOTECH AG 5-Tage-Chart

Aktuelle News zur VERAXA BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.09.VERAXA Biotech Appoints Raju Willener As Chief Financial Officer7
04.09.Veraxa Biotech Names Raju Willener CFO4
04.09.Veraxa Biotech AG - Post de-SPAC - 6-K, Report of foreign issuer3
04.09.Veraxa Biotech ernennt Raju Willener zum neuen Finanzvorstand3
04.09.Veraxa Biotech names Raju Willener as chief financial officer2
04.09.VERAXA Biotech names Raju Willener as CFO2
VERAXA BIOTECH Aktie jetzt für 0€ handeln
04.09.Veraxa Biotech AG: VERAXA Biotech Appoints Raju Willener as Chief Financial Officer370Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company's pipeline of potential best-in-class therapies led by its...
► Artikel lesen
24.08.Veraxa Biotech AG - Post de-SPAC - 6-K, Report of foreign issuer2
24.08.Veraxa Biotech AG: VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance428Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties' technologies and expertiseZURICH, SWITZERLAND...
► Artikel lesen
05.08.Veraxa Biotech Holding AG - F-1/A, Registration statement for certain foreign private issuers19
31.07.Veraxa Biotech Holding AG - F-1, Registration statement for certain foreign private issuers6
29.07.Veraxa Biotech files first BiTAC patent applications in 20265
29.07.Veraxa Biotech AG: VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates964First BiTAC-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology...
► Artikel lesen
27.07.Veraxa advances cancer therapy program with OmniAb10
27.07.Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb569VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies...
► Artikel lesen
27.07.Veraxa treibt Krebstherapie-Programm mit OmniAb voran9
27.07.Veraxa Biotech Holding AG - 6-K, Report of foreign issuer3
24.07.Veraxa Biotech shareholders approve governance changes3
24.07.Veraxa Biotech: Aktionäre genehmigen weitreichende Satzungsänderungen15
24.07.Veraxa Biotech AG: VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth867ZURICH, SWITZERLAND, July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in the design and development of next-generation cancer therapeutics, held an Extraordinary...
► Artikel lesen
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1